13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001608126
Total reported value
$2.8B
$2.8B
25 檔
40.3%
As reported in its official Q1 2025 Form 13F filing, Finepoint Capital LP's tracked investment portfolio stood at $2.8B with 25 total positions.
In Q1 2025, Finepoint Capital LP displayed an active expansion posture, initiating 25 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including SPY, QXO, IWM) accounted for 40.3% of total reported equity market value during Q1 2025.
Top New Position Initiated
SPY
市值: $422.2M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 32.20% | +10.54% | — | |
| 2 | QXO | Qxo Inc | Stock-Industrials | 25.27% | -2.60% | -1.87% | |
| 3 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 22.59% | — | — | |
| 4 | LBRDK | Liberty Broadband-c | Stock-Comm Services | 3.43% | — | -73.74% | |
| 5 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.45% | — | -2.69% | |
| 6 | LLYVK* | Liberty Media Corp-liberty-c | Stock-Other | 2.25% | — | -46.74% | |
| 7 | ASND | Ascendis Pharma A/S | Stock-Other | 2.14% | — | -2.70% | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.86% | — | -2.68% | |
| 9 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.30% | — | -2.71% | |
| 10 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.26% | — | -2.69% | |
| 11 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.95% | — | -2.67% | |
| 12 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.86% | — | -2.71% | |
| 13 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.77% | — | -2.70% | |
| 14 | PRTA | Prothena Corporation plc | Stock-Other | 0.60% | — | -2.59% | |
| 15 | XNCR | Xencor Inc | Stock-Other | 0.52% | — | -2.70% | |
| 16 | EYPT | Eyepoint Inc | Stock-Other | 0.45% | — | -2.62% | |
| 17 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.42% | — | -2.67% | |
| 18 | ARVN | Arvinas Inc | Stock-Other | 0.37% | — | -2.77% | |
| 19 | SLDB | Solid Biosciences Inc | Stock-Other | 0.27% | — | — | |
| 20 | ANNA | Aleanna Inc | Stock-Other | 0.02% | -0.01% | — | |
| 21 | ANNAW | Aleanna Inc - Cl A - 29 | Stock-Other | 0.01% | -0.01% | — | |
| 22 | ✓ | Marblegate Acquisition CORP | Stock-Other | 0.01% | — | — | |
| 23 | ✓ | Moneyhero Limited | Stock-Other | — | — | — | |
| 24 | ✓ | Summit Healthcare Acquisition | Stock-Other | — | — | — | |
| 25 | ✓ | Calidi Biotherapeutics Inc | Stock-Other | — | — | -0.01% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 2 | QXO | Qxo Inc | — | NEW | New buy |
| 3 | IWM | Ishares Russell 2000 ETF | — | NEW | New buy |
| 4 | LBRDK | Liberty Broadband-c | — | NEW | New buy |
| 5 | SWTXUSD | Springworks Therapeutics Inc | — | NEW | New buy |
| 6 | LLYVK* | Liberty Media Corp-liberty-c | — | NEW | New buy |
| 7 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 8 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 9 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 10 | LKFT | Lakefront Biotherapeutic-adr | — | NEW | New buy |
| 11 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 12 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 13 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 14 | PRTA | Prothena Corporation plc | — | NEW | New buy |
| 15 | XNCR | Xencor Inc | — | NEW | New buy |
| 16 | EYPT | Eyepoint Inc | — | NEW | New buy |
| 17 | RLAY | Relay Therapeutics Inc | — | NEW | New buy |
| 18 | ARVN | Arvinas Inc | — | NEW | New buy |
| 19 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 20 | ANNA | Aleanna Inc | — | NEW | New buy |
| 21 | ANNAW | Aleanna Inc - Cl A - 29 | — | NEW | New buy |
| 22 | ✓ | Marblegate Acquisition CORP | — | NEW | New buy |
| 23 | ✓ | Moneyhero Limited | — | NEW | New buy |
| 24 | ✓ | Summit Healthcare Acquisition | — | NEW | New buy |
| 25 | ✓ | Calidi Biotherapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Finepoint Capital LP reported a total U.S. public equity portfolio value of $2.8B across 25 disclosed positions in Q1 2025.
During Q1 2025, Finepoint Capital LP's top holdings by market value included SPY (32.2%)、QXO (25.3%)、IWM (22.6%). The largest single position, SPY, represented 32.2% of total portfolio value.
In Q1 2025, Finepoint Capital LP made 25 total portfolio adjustments, initiating 25 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.